Skip to main content
. Author manuscript; available in PMC: 2023 Mar 14.
Published in final edited form as: J Immunol. 2019 Sep 18;203(8):2043–2048. doi: 10.4049/jimmunol.1801327

Figure 1: ROR1 is highly expressed in MCL cells poorly responsive to BTK inhibitor.

Figure 1:

(A) Impact of BTK inhibitor Ibrutinib on growth MCL cell lines (JeKo-1, Mino, Mino, SP49, and MCL-RL) evaluated using MTT conversion assay at 48 h. The results are representative of three experiments; the bars reflect the SD values of experimental triplicates. (B) Expression of ROR1 by MCL cell lines and primary cells detected by flow cytometry. (C) Expression of CD19 in the MCL cell lines and patient samples evaluated by flow cytometry.